Compare Albemarle Corp. (ALB) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Albemarle Corp. vs Enveric Biosciences Inc — how do they compare? Albemarle Corp. trades at $128.55 (market cap $15.22B), while Enveric Biosciences Inc trades at $1.37 (market cap $5.84M). The key difference: Albemarle Corp. is far larger — about 2606.2× Enveric Biosciences Inc's market cap, and Albemarle Corp. pays a 1.26% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ALB | ENVB | |
|---|---|---|
Market Cap | $15.22B | $5.84M |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $17.40 |
52-Week Low | $67.30 | $1.28 |
Enterprise Value | $18.24B | $932.52K |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albemarle (ALB) is trading at $129.02, down 4.82% over the past 24 hours amid bearish technical signals. The stock shows mixed fundamentals with a low P/E of 5.12 and negative net income margin of -4.24% for 2025, though Q1 2026 earnings beat expectations. Recent news highlights a focus on debt reduction and energy storage system demand as lithium prices rebound. Cash flow improved in 2025 with net cash flow of $425.77 million, while the balance sheet reflects a debt-to-asset ratio of 19.8%.
The outlook for ALB hinges on lithium price recovery and execution in energy storage markets. Analyst consensus is mixed with a $227.10 price target suggesting significant upside, but risks include volatile lithium markets and ongoing profitability challenges. The stock's current level near key support at $128 may attract value investors, though macroeconomic and commodity pressures remain headwinds.
ENVB trades at $1.48, up 2.07% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, with negative ROE and ROA, yet consistently beat earnings expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies.
The outlook is mixed: strong analyst support (75% buy ratings) and positive clinical updates contrast with deep losses and bearish technicals. Key risks include clinical trial outcomes and cash burn, while institutional financing provides near-term stability. Upside depends on successful drug development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
